Cost-effectiveness of schizophrenia pharmacotherapy [1]

American Journal of Psychiatry

Volumn 164, Issue 4, 2007, Pages 678-

  Soumerai, Stephen B ^a   Law, Michael R ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

NEUROLEPTIC AGENT; PERPHENAZINE;

COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG EFFICACY; HEALTH CARE POLICY; HUMAN; LETTER; MEDICAID; PRIORITY JOURNAL; SCHIZOPHRENIA; TARDIVE DYSKINESIA;

EID: 34247515417     PISSN: 0002953X     EISSN: None     Source Type: Journal    
DOI: 10.1176/ajp.2007.164.4.678     Document Type: Letter

References (3)

1. Rosenheck RA, Leslie DL, Sindelar J, Miller EA, Lin H, Stroup TS, McEvoy J, Davis SM, Keefe RSE, Swartz M, Perkins DO, Hsiao JK, Lieberman J: Cost-effectiveness of second-generation antipsychotics and perphenazine in a randomized trial of treatment for chronic schizophrenia. Am J Psychiatry 2006; 163:2080-2089
2. Russell LB, Gold MR, Siegel JE, Daniels N, Weinstein MC: The role of cost-effectiveness analysis in health and medicine. JAMA 1996; 276:1172-1177
3. Correll CU, Leucht S, Kane JM: Lower risk for tardive dyskinesia associated with second-generation antipsychotics: a systematic review of 1-year studies. Am J Psychiatry 2004; 161:414-425